Paradigm Biopharmaceuticals Limited (ASX:PAR) Insider Buys A$2,590,844.00 in Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie acquired 5,181,688 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The stock was purchased at an average cost of A$0.50 ($0.32) per share, for a total transaction of A$2,590,844.00 ($1,660,797.44).

Paradigm Biopharmaceuticals Price Performance

The company has a market cap of $196.66 million, a PE ratio of -2.47 and a beta of 0.94. The company has a current ratio of 7.22, a quick ratio of 5.93 and a debt-to-equity ratio of 1.01.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.